NASDAQ:IMCR Immunocore Q3 2024 Earnings Report $28.05 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$28.04 0.00 (-0.02%) As of 05/15/2026 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunocore EPS ResultsActual EPS$0.17Consensus EPS -$0.33Beat/MissBeat by +$0.50One Year Ago EPS-$0.59Immunocore Revenue ResultsActual Revenue$80.25 millionExpected Revenue$78.94 millionBeat/MissBeat by +$1.31 millionYoY Revenue Growth+23.70%Immunocore Announcement DetailsQuarterQ3 2024Date11/6/2024TimeBefore Market OpensConference Call DateWednesday, November 6, 2024Conference Call Time7:00AM ETUpcoming EarningsImmunocore's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunocore Earnings HeadlinesImmunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 ShMay 14, 2026 | cnn.comA Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival DataMay 8, 2026 | finance.yahoo.comYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - at no charge. Inside, he reveals the one options technique that took him 11 years to find, why more strategies often lead to more losses, and the 10-minute nightly routine that replaced his 8-hour trading days. | Profits Run (Ad)Immunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And EfficiencyMay 7, 2026 | finance.yahoo.comImmunocore reports first quarter financial results and provides a business updateMay 6, 2026 | globenewswire.comKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaApril 19, 2026 | globenewswire.comSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need. The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma. Beyond this, Immunocore’s pipeline includes multiple additional ImmTAC candidates in various stages of clinical evaluation across solid tumor indications such as colorectal, lung and other metastatic cancers. The firm also pursues collaborations with major biopharmaceutical partners to expand the reach and application of its TCR technology, notably with Genentech and Fosun Pharma. Headquartered in Oxford, England, with research and development facilities in Philadelphia, Pennsylvania, Immunocore leverages a global infrastructure to support its clinical trials and manufacturing efforts. Founded in 2008, the company is led by Chief Executive Officer Dr. Bahija Jallal, under whose direction Immunocore has advanced its first‐in‐class therapies from discovery through late‐stage clinical development. With a commitment to innovation in immune‐based medicine, Immunocore continues to explore new targets and indications that may benefit from the specificity and potency of its TCR‐based platform.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different StoriesViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying Opportunity Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
